$16.2 Billion is the total value of Baker Brothers Advisors's 110 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 25.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Buy | Seattle Genetics, Inc. | $5,775,950,000 | +1.0% | 50,060,240 | +0.0% | 35.57% | +17.0% |
| INCY | Buy | Incyte Corporation | $2,341,806,000 | -16.1% | 31,978,785 | +0.0% | 14.42% | -2.8% |
| ACAD | Buy | ACADIA Pharmaceuticals Inc. | $1,770,469,000 | +1.3% | 41,904,586 | +2.6% | 10.90% | +17.3% |
| BGNE | BeiGene, Ltd.sponsored adr | $1,449,902,000 | -25.7% | 11,777,285 | 0.0% | 8.93% | -14.0% | |
| ALXN | Buy | Alexion Pharmaceuticals, Inc. | $786,632,000 | -11.9% | 8,760,794 | +6.1% | 4.84% | +2.0% |
| BMRN | BioMarin Pharmaceutical Inc. | $641,295,000 | -0.1% | 7,589,294 | 0.0% | 3.95% | +15.8% | |
| KOD | Buy | Kodiak Sciences Inc. | $552,105,000 | -30.5% | 11,574,538 | +4.8% | 3.40% | -19.5% |
| ASND | Ascendis Pharma A/Ssponsored adr | $381,778,000 | -19.1% | 3,390,270 | 0.0% | 2.35% | -6.2% | |
| IGMS | IGM Biosciences, Inc. | $176,536,000 | +47.1% | 3,144,000 | 0.0% | 1.09% | +70.4% | |
| AMRN | Amarin Corporation plcsponsored adr | $137,987,000 | -81.3% | 34,496,685 | 0.0% | 0.85% | -78.4% | |
| ARGX | argenx SEsponsored adr | $134,306,000 | -17.9% | 1,019,557 | 0.0% | 0.83% | -4.9% | |
| NVTA | Buy | Invitae Corporation | $124,405,000 | -15.2% | 9,100,615 | +0.0% | 0.77% | -1.8% |
| PRNB | Buy | Principia Biopharma Inc. | $116,112,000 | +18.5% | 1,955,413 | +9.4% | 0.72% | +37.2% |
| MRTX | Buy | Mirati Therapeutics, Inc. | $108,370,000 | -35.7% | 1,409,784 | +7.8% | 0.67% | -25.6% |
| NBIX | Sell | Neurocrine Biosciences, Inc. | $107,343,000 | -20.4% | 1,240,243 | -1.1% | 0.66% | -7.8% |
| EXAS | Sell | Exact Sciences Corporation | $107,076,000 | -55.2% | 1,846,139 | -28.6% | 0.66% | -48.2% |
| RARX | Ra Pharmaceuticals, Inc. | $100,525,000 | +2.3% | 2,093,839 | 0.0% | 0.62% | +18.6% | |
| MDGL | Buy | Madrigal Pharmaceuticals, Inc. | $100,087,000 | -6.1% | 1,499,212 | +28.2% | 0.62% | +8.8% |
| MYOK | MyoKardia, Inc. | $83,176,000 | -35.7% | 1,774,234 | 0.0% | 0.51% | -25.5% | |
| HRTX | Heron Therapeutics, Inc. | $70,653,000 | -50.0% | 6,018,104 | 0.0% | 0.44% | -42.2% | |
| CERS | Buy | Cerus Corporation | $63,766,000 | +40.6% | 13,713,195 | +27.6% | 0.39% | +63.1% |
| ZYME | Zymeworks Inc. | $60,600,000 | -22.0% | 1,708,472 | 0.0% | 0.37% | -9.7% | |
| TCDA | Buy | Tricida, Inc. | $58,652,000 | -21.1% | 2,666,015 | +35.3% | 0.36% | -8.6% |
| BCEL | Atreca, Inc. | $58,467,000 | +7.0% | 3,532,760 | 0.0% | 0.36% | +23.7% | |
| DBVT | DBV Technologies S.A.sponsored adr | $57,288,000 | -63.4% | 14,614,264 | 0.0% | 0.35% | -57.5% | |
| AXSM | Buy | Axsome Therapeutics, Inc. | $52,344,000 | -39.0% | 889,757 | +7.2% | 0.32% | -29.4% |
| INSM | Buy | Insmed Incorporated | $48,497,000 | -16.9% | 3,025,384 | +23.7% | 0.30% | -3.5% |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $43,337,000 | +40.0% | 2,799,577 | 0.0% | 0.27% | +61.8% | |
| RYTM | Rhythm Pharmaceuticals, Inc. | $41,219,000 | -33.7% | 2,708,200 | 0.0% | 0.25% | -23.3% | |
| KRYS | Sell | Krystal Biotech, Inc. | $40,925,000 | -28.6% | 946,471 | -8.5% | 0.25% | -17.4% |
| Neurocrine Biosciences, Inc.note 2.25% 5/15/2024 | $39,321,000 | -16.6% | 30,770,000 | 0.0% | 0.24% | -3.6% | ||
| NLTX | Neoleukin Therapeutics, Inc. | $38,666,000 | -7.6% | 3,397,740 | 0.0% | 0.24% | +6.7% | |
| CCXI | Buy | ChemoCentryx, Inc. | $34,515,000 | +18.1% | 859,015 | +16.2% | 0.21% | +37.4% |
| ALLK | Buy | Allakos Inc. | $32,721,000 | +1.0% | 735,469 | +116.5% | 0.20% | +17.4% |
| GWPH | GW Pharmaceuticals plcads | $32,475,000 | -16.2% | 370,845 | 0.0% | 0.20% | -2.9% | |
| MRUS | Merus N.V. | $24,653,000 | -14.1% | 2,037,469 | 0.0% | 0.15% | -0.7% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $24,695,000 | -28.4% | 1,701,929 | 0.0% | 0.15% | -16.9% | |
| APLS | Buy | Apellis Pharmaceuticals, Inc. | $24,019,000 | +57.8% | 896,551 | +80.4% | 0.15% | +82.7% |
| ASMB | Assembly Biosciences, Inc. | $22,862,000 | -27.5% | 1,541,618 | 0.0% | 0.14% | -16.1% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $21,892,000 | -42.0% | 10,946,166 | 0.0% | 0.14% | -32.8% | |
| FREQ | Sell | Frequency Therapeutics, Inc. | $21,019,000 | -2.6% | 1,180,162 | -4.2% | 0.13% | +12.2% |
| ADPT | Sell | Adaptive Biotechnologies Corporation | $20,661,000 | -38.1% | 743,734 | -33.3% | 0.13% | -28.2% |
| ALKS | Buy | Alkermes plc | $17,949,000 | +10.9% | 1,244,744 | +56.9% | 0.11% | +29.1% |
| QURE | Sell | uniQure N.V. | $16,944,000 | -54.3% | 357,083 | -31.0% | 0.10% | -47.2% |
| BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $15,576,000 | -1.7% | 15,000,000 | 0.0% | 0.10% | +14.3% | ||
| XNCR | Xencor, Inc. | $12,792,000 | -13.1% | 428,120 | 0.0% | 0.08% | +1.3% | |
| URGN | Sell | UroGen Pharma Ltd. | $12,005,000 | -56.7% | 672,912 | -19.1% | 0.07% | -50.0% |
| PTGX | Buy | Protagonist Therapeutics, Inc. | $11,855,000 | +43.2% | 1,679,164 | +43.0% | 0.07% | +65.9% |
| ADAP | New | Adaptimmune Therapeutics plcsponsored adr | $10,038,000 | – | 3,690,307 | +100.0% | 0.06% | – |
| AIMT | Aimmune Therapeutics, Inc. | $9,718,000 | -56.9% | 673,908 | 0.0% | 0.06% | -50.0% | |
| UROV | Urovant Sciences Ltd. | $9,220,000 | -40.6% | 1,000,000 | 0.0% | 0.06% | -30.5% | |
| MIRM | Buy | Mirum Pharmaceuticals, Inc. | $8,167,000 | -0.1% | 583,333 | +75.0% | 0.05% | +16.3% |
| RETA | Buy | Reata Pharmaceuticals, Inc.cl a | $8,081,000 | -3.5% | 55,983 | +36.6% | 0.05% | +11.1% |
| AGLE | Aeglea BioTherapeutics, Inc. | $7,985,000 | -39.0% | 1,713,604 | 0.0% | 0.05% | -30.0% | |
| IFRX | Inflarx N.V. | $6,794,000 | -3.5% | 1,778,415 | 0.0% | 0.04% | +13.5% | |
| ALEC | New | Alector, Inc. | $6,756,000 | – | 280,000 | +100.0% | 0.04% | – |
| SGMO | Sangamo Therapeutics, Inc. | $6,369,000 | -23.9% | 999,823 | 0.0% | 0.04% | -11.4% | |
| BDSI | New | BioDelivery Sciences International, Inc. | $6,209,000 | – | 1,638,334 | +100.0% | 0.04% | – |
| FLGT | Fulgent Genetics, Inc. | $6,127,000 | -16.6% | 569,444 | 0.0% | 0.04% | -2.6% | |
| ALBO | Buy | Albireo Pharma, Inc. | $6,041,000 | -4.9% | 369,047 | +47.6% | 0.04% | +8.8% |
| IDRA | Idera Pharmaceuticals, Inc. | $6,084,000 | -27.5% | 4,608,786 | 0.0% | 0.04% | -17.8% | |
| HOOK | Sell | HOOKIPA Pharma Inc. | $5,779,000 | -47.1% | 700,481 | -21.5% | 0.04% | -37.9% |
| HZNP | New | Horizon Therapeutics Public Ltd Co | $5,924,000 | – | 200,000 | +100.0% | 0.04% | – |
| ISEE | Buy | IVERIC bio, Inc. | $5,626,000 | +362.7% | 1,635,501 | +1053.8% | 0.04% | +483.3% |
| CABA | Cabaletta Bio, Inc. | $4,645,000 | -47.8% | 636,363 | 0.0% | 0.03% | -38.3% | |
| TARA | New | ArTara Therapeutics, Inc. | $4,592,000 | – | 199,671 | +100.0% | 0.03% | – |
| MLND | Millendo Therapeutics, Inc. | $4,400,000 | -21.7% | 833,333 | 0.0% | 0.03% | -10.0% | |
| PASG | New | Passage Bio, Inc. | $4,331,000 | – | 275,000 | +100.0% | 0.03% | – |
| IMMU | New | Immunomedics, Inc. | $4,179,000 | – | 310,000 | +100.0% | 0.03% | – |
| CNST | Constellation Pharmaceuticals, Inc. | $4,191,000 | -33.3% | 133,333 | 0.0% | 0.03% | -21.2% | |
| NERV | New | Minerva Neurosciences, Inc. | $4,145,000 | – | 688,531 | +100.0% | 0.03% | – |
| SYRS | Syros Pharmaceuticals, Inc. | $4,093,000 | -14.2% | 690,167 | 0.0% | 0.02% | 0.0% | |
| CPRX | Sell | Catalyst Pharmaceuticals, Inc. | $4,084,000 | -18.8% | 1,060,714 | -21.0% | 0.02% | -7.4% |
| ABEO | Sell | Abeona Therapeutics Inc. | $3,340,000 | -55.4% | 1,590,686 | -30.5% | 0.02% | -47.5% |
| ANAB | Buy | AnaptysBio, Inc. | $3,315,000 | +80.4% | 234,592 | +107.4% | 0.02% | +100.0% |
| EVFM | Sell | Evofem Biosciences, Inc. | $3,305,000 | -29.2% | 621,297 | -17.9% | 0.02% | -20.0% |
| NGM | NGM Biopharmaceuticals, Inc. | $3,083,000 | -33.3% | 250,000 | 0.0% | 0.02% | -24.0% | |
| KRTX | New | Karuna Therapeutics, Inc. | $3,022,000 | – | 41,976 | +100.0% | 0.02% | – |
| MTEM | Sell | Molecular Templates, Inc. | $3,162,000 | -28.6% | 237,917 | -24.9% | 0.02% | -20.8% |
| ORTX | Orchard Therapeutics plcads | $3,055,000 | -45.2% | 405,702 | 0.0% | 0.02% | -36.7% | |
| ARAV | Buy | Aravive, Inc. | $2,801,000 | -52.7% | 486,333 | +12.2% | 0.02% | -45.2% |
| MRKR | Sell | Marker Therapeutics, Inc. | $2,793,000 | -35.3% | 1,470,198 | -2.0% | 0.02% | -26.1% |
| GLPG | Galapagos NVsponsored adr | $2,561,000 | -5.3% | 13,072 | 0.0% | 0.02% | +14.3% | |
| CRNX | Crinetics Pharmaceuticals, Inc. | $2,573,000 | -41.4% | 175,000 | 0.0% | 0.02% | -30.4% | |
| GBT | New | Global Blood Therapeutics, Inc. | $2,401,000 | – | 47,000 | +100.0% | 0.02% | – |
| XLRN | New | Acceleron Pharma Inc. | $2,426,000 | – | 27,000 | +100.0% | 0.02% | – |
| HARP | Sell | Harpoon Therapeutics, Inc. | $2,368,000 | -25.3% | 204,467 | -4.6% | 0.02% | -11.8% |
| MTNB | Buy | Matinas BioPharma Holdings, Inc. | $2,253,000 | -62.3% | 3,754,221 | +42.6% | 0.01% | -56.2% |
| APLT | New | Applied Therapeutics, Inc. | $2,155,000 | – | 65,934 | +100.0% | 0.01% | – |
| VKTX | Viking Therapeutics, Inc. | $1,989,000 | -41.7% | 425,000 | 0.0% | 0.01% | -33.3% | |
| BLUE | bluebird bio, Inc. | $1,838,000 | -47.6% | 40,000 | 0.0% | 0.01% | -42.1% | |
| DNLI | New | Denali Therapeutics Inc. | $1,837,000 | – | 104,900 | +100.0% | 0.01% | – |
| NTLA | Intellia Therapeutics, Inc. | $1,572,000 | -16.6% | 128,538 | 0.0% | 0.01% | 0.0% | |
| LPTX | Leap Therapeutics, Inc. | $1,546,000 | +41.1% | 978,454 | 0.0% | 0.01% | +66.7% | |
| RCUS | Arcus Biosciences, Inc. | $1,687,000 | +37.5% | 121,534 | 0.0% | 0.01% | +42.9% | |
| MNLO | Sell | Menlo Therapeutics Inc. | $1,676,000 | -48.4% | 625,345 | -10.7% | 0.01% | -41.2% |
| DRNA | New | Dicerna Pharmaceuticals, Inc. | $1,505,000 | – | 81,935 | +100.0% | 0.01% | – |
| ARYA | New | ARYA Sciences Acquisition Corp. | $1,527,000 | – | 150,000 | +100.0% | 0.01% | – |
| New | Bellicum Pharmaceuticals, Inc. | $1,173,000 | – | 249,123 | +100.0% | 0.01% | – | |
| AUTL | Autolus Therapeutics plcspon ads | $939,000 | -54.6% | 156,773 | 0.0% | 0.01% | -45.5% | |
| GTHX | Sell | G1 Therapeutics, Inc. | $970,000 | -71.2% | 88,026 | -30.8% | 0.01% | -66.7% |
| GLMD | Galmed Pharmaceuticals Ltd. | $746,000 | -40.1% | 215,594 | 0.0% | 0.01% | -28.6% | |
| IDYA | Sell | IDEAYA Biosciences, Inc. | $522,000 | -65.2% | 126,611 | -36.7% | 0.00% | -62.5% |
| ADMS | Adamas Pharmaceuticals, Inc. | $499,000 | -23.7% | 172,630 | 0.0% | 0.00% | 0.0% | |
| INFI | Infinity Pharmaceuticals, Inc. | $486,000 | -12.7% | 580,400 | 0.0% | 0.00% | 0.0% | |
| AFMD | Affimed N.V. | $316,000 | -42.3% | 200,000 | 0.0% | 0.00% | -33.3% | |
| GNFT | New | Genfit SAads | $395,000 | – | 26,696 | +100.0% | 0.00% | – |
| OVID | New | Ovid Therapeutics Inc. | $207,000 | – | 69,471 | +100.0% | 0.00% | – |
| SNSS | Sunesis Pharmaceuticals, Inc. | $231,000 | +22.9% | 556,665 | 0.0% | 0.00% | 0.0% | |
| CTMX | Sell | CytomX Therapeutics, Inc. | $153,000 | -90.5% | 20,000 | -89.7% | 0.00% | -88.9% |
| DVAX | Exit | Dynavax Technologies Corporation | $0 | – | -75,000 | -100.0% | -0.00% | – |
| SBPH | Exit | Spring Bank Pharmaceuticals, Inc. | $0 | – | -613,144 | -100.0% | -0.01% | – |
| Exit | Trillium Therapeutics Inc. | $0 | – | -1,100,000 | -100.0% | -0.01% | – | |
| BLCM | Exit | Bellicum Pharmaceuticals, Inc. | $0 | – | -2,677,818 | -100.0% | -0.02% | – |
| YMAB | Exit | Y-mAbs Therapeutics, Inc. | $0 | – | -138,514 | -100.0% | -0.02% | – |
| NXTC | Exit | NextCure, Inc. | $0 | – | -150,000 | -100.0% | -0.04% | – |
| BOLD | Exit | Audentes Therapeutics, Inc. | $0 | – | -804,720 | -100.0% | -0.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.